Letter: Effects of Dapagliflozin on Endothelial Function Renal Injury Markers and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)

摘要

We have read with great interest the elegant paper by Kong et al. [ ], demonstrating that administration of dapagliflozin in drug-naïve patients with type 2 diabetes mellitus (T2DM) did not affect significantly systemic endothelial function, as measured by the reactive hyperemic index (RHI); however, it produced a significant decrease in body weight and homeostatic model assessment of insulin resistance (HOMA-IR) and promoted enhanced ketogenesis.